---
title: "Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Safety questions"
description: "Safety questions on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Can people with a milk protein allergy use Trelegy? What Trelegy side effects were reported after approval? Can Trelegy cause oral thrush (candidiasis)? Can Trelegy cause glaucoma or cataracts? 10 further questions follow. 14 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trelegy-ellipta/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Safety questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Trelegy Ellipta](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF)  
Indication pages: [Chronic obstructive pulmonary disease](https://www.evicenter.com/medical-information/trelegy-ellipta--chronic-obstructive-pulmonary-disease)

## Warnings

<a id="trelegy-milk-allergy"></a>

### Can people with a milk protein allergy use Trelegy?

> “Patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate (FF), umeclidinium (UMEC), vilanterol (VI), or any of the excipients.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Patients%20with%20severe%20hypersensitivity%20to,or%20any%20of%20the%20excipients.)

> “There have been reports of anaphylactic reactions in patients with severe milk protein 
> allergy after inhalation of other powder medications containing lactose; therefore, patients with 
> severe milk protein allergy should not use TRELEGY ELLIPTA”

Source: [TRELEGY ELLIPTA: Prescribing information, page 10, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=10)

Note: The first passage is the second contraindication listed in the Important Safety Information.

<a id="trelegy-oral-thrush"></a>

### Can Trelegy cause oral thrush (candidiasis)?

> “Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing fluticasone furoate. Advise patients to rinse their mouths with water without swallowing after inhalation.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Oropharyngeal%20candidiasis%20has%20occurred%20in,water%20without%20swallowing%20after%20inhalation.)

> “In some cases, therapy with TRELEGY ELLIPTA may need to be 
> interrupted. Advise the patient to rinse his/her mouth with water without swallowing following 
> administration of TRELEGY ELLIPTA to help reduce the risk of oropharyngeal candidiasis.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=7)

<a id="trelegy-glaucoma-cataracts"></a>

### Can Trelegy cause glaucoma or cataracts?

> “Glaucoma, increased intraocular pressure, and cataracts have been reported following the long-term administration of ICS or inhaled anticholinergics. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use TRELEGY long term.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Glaucoma%2C%20increased%20intraocular%20pressure%2C%20and,or%20use%20TRELEGY%20long%20term.)

> “Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a healthcare provider immediately if signs or symptoms of acute narrow-angle glaucoma develop.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Use%20with%20caution%20in%20patients,of%20acute%20narrow%2Dangle%20glaucoma%20develop.)

> “Prescribers and patients should also be alert for signs and symptoms of acute 
> narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored 
> images in association with red eyes from conjunctival congestion and corneal edema).”

Source: [TRELEGY ELLIPTA: Prescribing information, page 11, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=11)

<a id="trelegy-urinary-retention"></a>

### Can Trelegy cause urinary retention?

> “Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if signs or symptoms of urinary retention develop.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Use%20with%20caution%20in%20patients%20with%20urinary,symptoms%20of%20urinary%20retention%20develop.)

> “Prescribers and patients should be alert for signs and 
> symptoms of urinary retention (e.g., difficulty passing urine, painful urination)”

Source: [TRELEGY ELLIPTA: Prescribing information, page 11, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=11)

<a id="trelegy-infections"></a>

### Does Trelegy increase the risk of infections such as chickenpox or tuberculosis?

> “A more serious or even fatal course of chickenpox or measles may occur in susceptible patients using corticosteroids. ICS should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=A%20more%20serious%20or%20even,infections%3B%20or%20ocular%20herpes%20simplex.)

> “Persons who are using drugs that suppress the immune system are more susceptible to infections 
> than healthy individuals.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=7)

<a id="trelegy-other-laba"></a>

### Can Trelegy be used with other LABA inhalers?

> “TRELEGY should not be used more often or at higher doses than recommended or with another LABA for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, like LABA.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20should%20not%20be%20used,inhaled%20sympathomimetic%20drugs%2C%20like%20LABA.)

> “Patients using TRELEGY 
> ELLIPTA should not use another therapy containing a LABA (e.g., salmeterol, formoterol 
> fumarate, arformoterol tartrate, indacaterol) for any reason.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=6)

<a id="trelegy-contraindications"></a>

### What are the contraindications for Trelegy?

> “TRELEGY is contraindicated in the following:
>
> Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
> Patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate (FF), umeclidinium (UMEC), vilanterol (VI), or any of the excipients.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=TRELEGY%20is%20contraindicated%20in%20the,or%20any%20of%20the%20excipients.)

<a id="trelegy-paradoxical-bronchospasm"></a>

### Can Trelegy cause paradoxical bronchospasm?

> “As with other inhaled therapies, TRELEGY ELLIPTA can produce paradoxical bronchospasm, 
> which may be life threatening. If paradoxical bronchospasm occurs following dosing with 
> TRELEGY ELLIPTA, it should be treated immediately with an inhaled, short-acting 
> bronchodilator; TRELEGY ELLIPTA should be discontinued immediately; and alternative 
> therapy should be instituted.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 9, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=9)

<a id="trelegy-allergic-reactions"></a>

### Can Trelegy cause allergic reactions?

> “Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of TRELEGY. Discontinue TRELEGY if such reactions occur.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Hypersensitivity%20reactions%20such%20as%20anaphylaxis%2C,TRELEGY%20if%20such%20reactions%20occur.)

<a id="trelegy-adrenal-suppression"></a>

### Can Trelegy cause adrenal suppression?

> “Hypercorticism and adrenal suppression may occur with higher than the recommended dosage or at the regular dosage of ICS in susceptible individuals. If such changes occur, reduce the dose of TRELEGY slowly and consider other treatments for management of COPD or asthma symptoms.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Hypercorticism%20and%20adrenal%20suppression%20may,of%20COPD%20or%20asthma%20symptoms.)

> “Inhaled fluticasone furoate is absorbed into the circulation and can be systemically active. 
> Effects of fluticasone furoate on the HPA axis are not observed with the therapeutic doses of 
> fluticasone furoate in TRELEGY ELLIPTA. However, exceeding the recommended dosage or 
> coadministration with a strong cytochrome P450 3A4 (CYP3A4) inhibitor may result in HPA 
> dysfunction”

Source: [TRELEGY ELLIPTA: Prescribing information, page 9, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=9)

<a id="trelegy-potassium-blood-sugar"></a>

### Can Trelegy lower potassium or raise blood sugar?

> “Beta-adrenergic agonist therapies may produce significant hypokalemia in some patients, 
> possibly through intracellular shunting, which has the potential to produce adverse 
> cardiovascular effects. The decrease in serum potassium is usually transient, not requiring 
> supplementation. Beta-agonist therapies may produce transient hyperglycemia in some patients.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=12)

> “Be alert to hypokalemia and hyperglycemia.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=Be%20alert%20to%20hypokalemia%20and%20hyperglycemia.)

## Side effects

<a id="trelegy-postmarketing-side-effects"></a>

### What Trelegy side effects were reported after approval?

> “In addition to adverse reactions reported from clinical trials, the following adverse reactions have 
> been identified during postapproval use of TRELEGY ELLIPTA. Because these reactions are 
> reported voluntarily from a population of uncertain size, it is not always possible to reliably 
> estimate their frequency or establish a causal relationship to drug exposure. These events have 
> been chosen for inclusion due to either their seriousness, frequency of reporting, or causal 
> connection to TRELEGY ELLIPTA or a combination of these factors. 
> Cardiac Disorders 
> Palpitations 
> Eye Disorders 
> Blurred vision, eye pain, glaucoma, and intraocular pressure increase. 
> Immune System Disorders 
> Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria. 
> Metabolism and Nutrition Disorders 
> Hyperglycemia 
> Musculoskeletal and Connective Tissue Disorders 
> Muscle spasms 
> Nervous System Disorders 
> Tremor 
> Psychiatric Disorders 
> Anxiety 
> Renal and Urinary Disorders 
> Dysuria, urinary retention.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 15, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=15)

## Safety

<a id="trelegy-report-side-effects"></a>

### How do I report Trelegy side effects?

> “To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
> FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

Source: [TRELEGY ELLIPTA: A COPD or Asthma Treatment, captured 2026-11-14](https://www.trelegyhcp.com/#:~:text=To%20report%20SUSPECTED%20ADVERSE%20REACTIONS%2C,FDA%20at%201%2D800%2DFDA%2D1088%20or%20www.fda.gov%2Fmedwatch.)

<a id="trelegy-overdose"></a>

### What happens with a Trelegy overdose?

> “TRELEGY ELLIPTA contains fluticasone furoate, umeclidinium, and vilanterol; therefore, the 
> risks associated with overdosage for the individual components described below apply to 
> TRELEGY ELLIPTA. Treatment of overdosage consists of discontinuation of TRELEGY 
> ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy. The 
> judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that 
> such medicine can produce bronchospasm. Cardiac monitoring is recommended in cases of 
> overdosage.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=21)

> “High doses of umeclidinium may lead to anticholinergic signs and symptoms.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=21)

> “The expected signs and symptoms with overdosage of vilanterol are those of excessive 
> beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms 
> of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia 
> with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry 
> mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, 
> metabolic acidosis). As with all inhaled sympathomimetic medicines, cardiac arrest and even 
> death may be associated with an overdose of vilanterol.”

Source: [TRELEGY ELLIPTA: Prescribing information, page 21, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF#page=21)

## Related pages
- [Medical information: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder): All indications](https://www.evicenter.com/medical-information/trelegy-ellipta)
- [Indication](https://www.evicenter.com/medical-information/trelegy-ellipta/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trelegy-ellipta/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/trelegy-ellipta/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/trelegy-ellipta/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trelegy-ellipta/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trelegy-ellipta/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trelegy-ellipta/access-and-coverage)
